Research Analysts Issue Forecasts for BCRX Q3 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Stock analysts at HC Wainwright raised their Q3 2026 earnings estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, June 30th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.05 per share for the quarter, up from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at ($2.74) EPS, FY2027 earnings at $0.55 EPS, FY2028 earnings at $0.50 EPS, FY2029 earnings at $1.12 EPS and FY2030 earnings at $2.49 EPS.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Finally, Citizens Jmp increased their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.67.

BioCryst Pharmaceuticals Stock Down 3.5%

Shares of NASDAQ:BCRX opened at $9.65 on Thursday. The company has a market cap of $2.45 billion, a P/E ratio of -5.42 and a beta of 0.55. The business has a fifty day simple moving average of $8.92 and a 200-day simple moving average of $8.30. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $10.94.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Pacer Advisors Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $14,880,000. Seven Fleet Capital Management LP purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at about $976,000. NewEdge Advisors LLC grew its stake in BioCryst Pharmaceuticals by 4.6% during the 1st quarter. NewEdge Advisors LLC now owns 52,326 shares of the biotechnology company’s stock valued at $498,000 after purchasing an additional 2,285 shares in the last quarter. Perceptive Advisors LLC grew its stake in BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in BioCryst Pharmaceuticals by 231.6% during the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after purchasing an additional 3,556,208 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.